ReviewMolecular biotechnology2004
Generation and production of engineered antibodies.
Review in Molecular biotechnology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.Polymer science & technology (Washington, D.C.) · 2025Review
- The reduced form of the antibody CH2 domain.Protein science : a publication of the Protein Society · 2021Article
- Directing evolution of novel ligands by mRNA display.Chemical Society reviews · 2021Review
- Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology.International journal of cell biology · 2013Article
- Isolation of alpaca anti-hapten heavy chain single domain antibodies for development of sensitive immunoassay.Analytical chemistry · 2012Article
- Efficient expression from one CMV enhancer controlling two core promoters.Molecular biotechnology · 2011Article
- Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.Journal of the American Chemical Society · 2010Article
- Single-batch production of recombinant human polyclonal antibodies.Molecular biotechnology · 2010Article
- A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.Cancer immunology, immunotherapy : CII · 2010Article
- Self-assembly of antibodies by chemical induction.Angewandte Chemie (International ed. in English) · 2008Article
- Recent advances in the generation of human monoclonal antibody.Cytotechnology · 2007Article
- Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview.Transgenic research · 2007Review
- A new generation of protein display scaffolds for molecular recognition.Protein science : a publication of the Protein Society · 2006Review
- Antibodies: an alternative for antibiotics?Poultry science · 2005Review
- In situ isolation of immunoglobulin sequences expressed by single tumor-infiltrating B cells using laser-assisted microdissection.Molecular biotechnology · 2005Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant antibodies, immunoglobulin fragments, and artificial antigen-binding molecules. Since the production of recombinant antibodies is a limiting factor in their availability, and a shortage is expected in the future, different expression systems for recombinant antibodies and transgenic organisms as bioreactors are also discussed, along with their advantages and drawbacks.
Indexed as
Identifiers
14734823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.